Skip to content

Comparison of 730 nm picosecond laser and 755 nm picosecond laser in the treatment of seborrheic keratosis

Comparison of 730 nm picosecond laser and 755 nm picosecond laser in the treatment of seborrheic keratosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075091
Enrollment
Unknown
Registered
2023-08-24
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seborrheic keratosis

Interventions

A:730nm picosecond laser treatment for left face, 755nm picosecond laser treatment for right face. Laser parameters: picosecond 730nm laser (PicoWay, Sanoron, Israel), Zoom mode, 3mm spot, 1.6-1.8J/cm
Or picosecond 755nm laser (PicoSure, SanoShow, USA), Zoom mode, 2.7-3mm spot, 2.88-3.49J/cm2, 1-2 passes in total.
B:730nm picosecond laser treatment for right side face, 755nm picosecond laser treatment for left side face. Laser parameters: picosecond 730nm laser (PicoWay, Sanoron, Israel), Zoom mode, 3mm spot, 1

Sponsors

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Volunteer to participate in this experiment and have signed an informed consent form. Follow up can be carried out as planned. Between the ages of 18 and 65 Our outpatient department diagnosed multiple seborrheic keratosis on the face.

Exclusion criteria

Exclusion criteria: Localized presence of Ota nevi, freckles, obvious post inflammatory pigmentation, and other pigmentation enhancing diseases, as well as active diseases such as psoriasis and eczema, may interfere with clinical efficacy evaluation. Current or previous skin cancer or precancerous lesions of the skin. Pregnant and lactating women, as well as those preparing for pregnancy during the trial period. Patients with mental illness. Individuals with severe liver and kidney diseases or autoimmune diseases. Individuals who have been treated with topical retinoic acid preparations or whitening agents within the previous month. Received treatment with scraping or complete removal, freezing, electrolysis, chemical stripping, or various laser equipment. People who are allergic to lidocaine. Patients who are unable or refuse to follow up at the scheduled time.

Design outcomes

Primary

MeasureTime frame
PGA;

Secondary

MeasureTime frame
GAIS;Subject satisfaction;VAS;

Countries

China

Contacts

Public ContactYan Yan

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

yanyan@psh.pumc.edu.cn+86 136 6134 8184

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026